Last reviewed · How we verify
Depo-Medrol — Competitive Intelligence Brief
marketed
Corticosteroid (glucocorticoid)
Glucocorticoid receptor
Immunology / Rheumatology / General anti-inflammatory
Small molecule
Live · refreshed every 30 min
Target snapshot
Depo-Medrol (Depo-Medrol) — Hamilton Health Sciences Corporation. Depo-Medrol is a corticosteroid that suppresses the immune system and reduces inflammation by inhibiting the production and release of inflammatory mediators.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Depo-Medrol TARGET | Depo-Medrol | Hamilton Health Sciences Corporation | marketed | Corticosteroid (glucocorticoid) | Glucocorticoid receptor | |
| Durezol | DIFLUPREDNATE | Novartis | marketed | difluprednate | Glucocorticoid receptor | 2008-01-01 |
| Arnuity Ellipta | FLUTICASONE FUROATE | Haleon Us Holdings | marketed | Corticosteroid | Glucocorticoid receptor | 2007-01-01 |
| Omnaris | Alvesco | Takeda Gmbh | marketed | ciclesonide | Glucocorticoid receptor | 2006-01-01 |
| Omnaris | CICLESONIDE | Covis | marketed | ciclesonide | Glucocorticoid receptor | 2006-01-01 |
| Mifeprex | MIFEPRISTONE | Corcept Therap | marketed | Progestin Antagonist [EPC] | Glucocorticoid receptor | 2000-01-01 |
| Lotemax | LOTEPREDNOL ETABONATE | Bausch Health | marketed | Corticosteroid | Glucocorticoid receptor | 1998-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Omnaris · 8371292 · US
- — Lotemax · 9056057 · Formulation · US
- — Lotemax · 9532955 · Method of Use · US
- — Lotemax · 10058511 · Formulation · US
- — Lotemax · 11219596 · Method of Use · US
- — Lotemax · 11219597 · Method of Use · US
- — Lotemax · 11596599 · Method of Use · US
- — Lotemax · 10857096 · Method of Use · US
- — Lotemax · 10864219 · Method of Use · US
- — Lotemax · 10945948 · Method of Use · US
- — Lotemax · 10940108 · Method of Use · US
- — Lotemax · 9737491 · Method of Use · US
- — Lotemax · 9827191 · Formulation · US
- — Lotemax · 11872318 · Formulation · US
- — Lotemax · 9393213 · Formulation · US
- — Lotemax · 10646436 · Formulation · US
- — Lotemax · 10993908 · Method of Use · US
- — Lotemax · 12115246 · Formulation · US
- — Lotemax · 10688045 · Formulation · US
- — Lotemax · 11642317 · Formulation · US
- — Lotemax · 10646437 · Formulation · US
- — Lotemax · 11534395 · Formulation · US
- — Lotemax · 10596107 · Formulation · US
Sponsor landscape (Corticosteroid (glucocorticoid) class)
- Assistance Publique - Hôpitaux de Paris · 3 drugs in this class
- Astellas Pharma Inc · 2 drugs in this class
- Sanofi · 2 drugs in this class
- Xinqiao Hospital of Chongqing · 2 drugs in this class
- Berinstein, Jeffrey · 2 drugs in this class
- Ain Shams University · 2 drugs in this class
- Children's Hospital of Philadelphia · 1 drug in this class
- Celgene · 1 drug in this class
- Hamilton Health Sciences Corporation · 1 drug in this class
- Erasme University Hospital · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Depo-Medrol CI watch — RSS
- Depo-Medrol CI watch — Atom
- Depo-Medrol CI watch — JSON
- Depo-Medrol alone — RSS
- Whole Corticosteroid (glucocorticoid) class — RSS
Cite this brief
Drug Landscape (2026). Depo-Medrol — Competitive Intelligence Brief. https://druglandscape.com/ci/depo-medrol. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab